FY2024 Earnings Forecast for ABCL Issued By Leerink Partnrs

AbCellera Biologics Inc. (NASDAQ:ABCL) – Equities research analysts at Leerink Partnrs dropped their FY2024 earnings estimates for AbCellera Biologics in a report issued on Tuesday, November 5th. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings of ($0.59) per share for the year, down from their previous estimate of ($0.56). The consensus estimate for AbCellera Biologics’ current full-year earnings is ($0.55) per share. Leerink Partnrs also issued estimates for AbCellera Biologics’ Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.63) EPS.

ABCL has been the topic of a number of other reports. Benchmark reissued a “hold” rating on shares of AbCellera Biologics in a research report on Tuesday. Stifel Nicolaus reiterated a “buy” rating and issued a $12.00 price objective (down previously from $14.00) on shares of AbCellera Biologics in a research note on Tuesday.

AbCellera Biologics Stock Performance

Shares of ABCL opened at $2.70 on Thursday. The firm has a market capitalization of $795.61 million, a P/E ratio of -4.46 and a beta of 0.35. The stock has a 50 day moving average price of $2.63 and a two-hundred day moving average price of $3.05. AbCellera Biologics has a 52 week low of $2.34 and a 52 week high of $6.05.

AbCellera Biologics (NASDAQ:ABCL) last issued its earnings results on Monday, November 4th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). AbCellera Biologics had a negative return on equity of 15.54% and a negative net margin of 533.32%. The firm had revenue of $6.51 million for the quarter, compared to analyst estimates of $8.95 million. During the same period in the previous year, the company earned ($0.10) earnings per share.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP boosted its position in shares of AbCellera Biologics by 20.1% during the 1st quarter. Baker BROS. Advisors LP now owns 27,525,640 shares of the company’s stock valued at $124,691,000 after acquiring an additional 4,615,887 shares during the last quarter. Citizens Financial Group Inc. RI purchased a new stake in AbCellera Biologics in the second quarter valued at approximately $923,000. Renaissance Technologies LLC increased its stake in AbCellera Biologics by 16.0% in the second quarter. Renaissance Technologies LLC now owns 1,728,603 shares of the company’s stock valued at $5,117,000 after acquiring an additional 239,000 shares during the last quarter. GSA Capital Partners LLP increased its stake in AbCellera Biologics by 991.3% in the third quarter. GSA Capital Partners LLP now owns 241,866 shares of the company’s stock valued at $629,000 after acquiring an additional 219,703 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ lifted its position in AbCellera Biologics by 104.9% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 308,567 shares of the company’s stock worth $913,000 after buying an additional 158,000 shares during the last quarter. Hedge funds and other institutional investors own 61.42% of the company’s stock.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.